002422SZSE
🚨 Material Event

Announcement Regarding Receipt of Related Payments by Kelun-Biotech from Yilun Biopharmaceutical

✨ AI Summary

Kelun-Biotech, a subsidiary of Sichuan Kelun Pharmaceutical, received RMB 602,509,600.00 from Yilun Biopharmaceutical for the out-licensing of YL201. This payment is part of a settlement agreement resolving disputes. The total amount received to date is RMB 702,721,325.78, impacting non-recurring gains.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002422

Stock Abbreviation: Kelun Pharmaceutical

Sichuan Kelun Pharmaceutical Co., Ltd.

Announcement Number: 2026-047

Announcement Regarding Receipt of Related Payments by Kelun-Biotech from Yilun Biopharmaceutical

The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and are free from any false representations, misleading statements, or material omissions.

Recently, Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received RMB 602,509,600.00 from Suzhou Yilun Biopharmaceutical Co., Ltd. (hereinafter referred to as "Yilun Biopharmaceutical") for the out-licensing of YL201, which is shared income payable to Kelun-Biotech, a subsidiary of the Company, Sichuan Kelun-B

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.